Women’s Coalition Against Cancer (WOCACA) in collaboration with Movendi International have called for increased awareness on the dangers and negative effects of alcohol consumption. WOCACA and Movendi International have made the call in their joint statement in commemoration of this year’s World Alcohol Free Day, which falls on October 2 annually. The two organizations have […]
Global Blood Therapeutics Inc. (NASDAQ:GBT) went down by -0.10% from its latest closing price compared to the recent 1-year high of $73.02. The company’s stock price has collected 0.62% of gains in the last five trading sessions. The Wall Street Journal reported on 08/08/22 that Pfizer Agrees to $5.4 Billion Deal for Global Blood Therapeutics … Global Blood Therapeutics Inc. (GBT) Reveals an Earnings Mystery Read More »
At last check on Thursday, Global Blood Therapeutics Inc.’s (NASDAQ:GBT) stock was down -$0.2, moving down -0.29 percent to $67.91. The average number of shares traded per day over the past five days has been 1,562,847 shares. 4 times new highs have been achieved over the past 5 days, with a -$0.05 fall in that time frame. In the last twenty days, the average volume was 2,762,707, while in the previous 50 days, it was 3,992,881.
DUBLIN, Sept. 30, 2022 /PRNewswire/ — The “Global Nephrotic Syndrome Diagnostics & Therapeutics Market Forecast, 2022-2028” report has been added to ResearchAndMarkets.com’s offering. The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of 5.6% during the forecast period. Nephrotic syndrome is a kidney disease in which the body excretes […] The post Global Nephrotic Syndrome Diagnostics & Therapeutics Market to Grow at 5.6% Annually Through 2028 – QNT...
From October 10 to 14, 2022 at the Dubai World Trade Centre, Gitex Global returns, its largest ever edition featuring 5,000 companies spanning 26 halls and two million sq ft of exhibition space, at an extraordinary 25% year-on-year increase, pushing its capacity limit at the venue
Sorrento Therapeutics, Inc. (NASDAQ:SRNE – Get Rating) fell 9.5% during mid-day trading on Thursday . The company traded as low as $1.53 and last traded at $1.53. 85,416 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 7,711,165 shares. The stock had previously closed at $1.69. Sorrento Therapeutics […]